

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 7/16/19

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2) VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2) Infringuinal revascularized PAD (2) Pediatric VTE (2)	Filed 12/18 Phase III Phase III Phase III	
	INVOKANA® (canagliflozin) apocritentan	Treatment of CKD in patients with T2DM (2) Difficult to treat hypertension (2)	Filed 3/19 Phase III	Phase III Phase III
Immunology	TREMFYA® (guselkumab)	Psoriatic arthritis Crohn's Disease Pediatric Psoriasis	Phase III Phase IIB/III Phase III	Phase III Phase IIB/III Phase III
	SIMPONI® STELARA® (ustekinumab)	Pediatric Ulcerative Colitis Pediatric Psoriasis (6-11 year olds) Ulcerative Colitis Lupus	Phase III Phase III Phase III Filed 12/18 Phase III	Phase III Phase III Filed 06/19 Filed 12/18 Phase III
Infectious Diseases and Vaccines	Rilpivirine Long Acting nanosuspension for injection pimodivir (JNJ-3872) VAC52150	HIV Infection Influenza A (2) Monovalent Ebola Virus Vaccine	Filed 04/19 Phase III Phase III	Phase III Phase III Phase III
	SPRAVATO™ (esketamine) ponesimod paliperidone palmitate 6 month long-acting injectable	Treatment-resistant depression Major depressive disorder at imminent risk for suicide Monotherapy for multiple sclerosis Treatment of Schizophrenia	Approved 3/19 Phase III Phase III Phase III	Filed 10/18 Phase III Phase III Phase III
Oncology	DARZALEX®	Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006, CASSIOPEIA) (2)	Filed 3/19	Filed 3/19
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY3008, MAIA) (2)	Approved 06/19	Filed 3/19
		Relapsed Refractory MM 1+ prior lines w/PomDex (2)	Phase III	Phase III
		Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2)	Phase III	Phase III
		Amyloidosis (AMY 3001) (2)	Phase III	Phase III
		Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (MMY3012, COLUMBA) (2)	Filed 7/19	Phase III
		Smoldering multiple myeloma (SMM3001) (2)	Phase III	Phase III
	IMBRUVICA® (ibrutinib)	Frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3019, CEPHEUS) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant eligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3014, PERSEUS) (2)	Phase III	Phase III
		Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
ERLEADA™ (apalutamide)	Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III	
	Previously untreated and relapsed/refractory patients with Waldenstrom's Macroglobulinemia in combination with Rituximab (PCYC-1127) (2)	Approved 8/18	Positive CHMP 6/19	
	Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)	Phase III	Phase III	
	Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Approved 1/19	Positive CHMP 6/19	
	Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (2)	Phase III	Phase III	
	Frontline Chronic graft-versus-host-disease (cGVHD) (2)	Phase III	Phase III	
	Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (PCYC-1143) (2)	Phase III	Phase III	
apalutamide/ abiraterone acetate BALVERSA™ (erdafitinib) niraparib (PARP inhibitor) niraparib / abiraterone acetate BCMA CAR-T	Metastatic castrate sensitive prostate cancer (TITAN) Localized prostate cancer Prostate Cancer metastatic castration resistant chemotherapy naïve	Filed 04/19 Phase III Phase III	Filed 06/19 Phase III Phase III	
	Urothelial cancer (2)	Approved 4/19	Phase III	
	L3 Prostate cancer metastatic castration-resistant L1 Prostate cancer metastatic castration resistant in combination with abiraterone acetate and Prednisone	Phase IIB Phase III	Phase IIB Phase III	
Pulmonary Hypertension	OPSUMIT®	Fontan-palliated in adolescent (>12 years old) and adult patients Pediatric pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension	Phase III Phase III Complete Response 1/19	Phase III Phase III Filed 8/18
	UPTRAVI®	Pulmonary arterial hypertension IV Chronic thromboembolic pulmonary hypertension	Phase III Phase III	Phase III Phase III

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir developed in collaboration with ViiV Healthcare Ltd; apocritentan developed in collaboration with Idorsia; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacocyclics, LLC, an AbbVie company Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech;

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of July 16, 2019

NMEs APPROVED 2019	NMEs IN REGISTRATION	NME PLANNED FILINGS 2019-2023*	
Oncology	Neuroscience	Oncology	Neuroscience
ERLEADA™ (apalutamide) (EU) Non-metastatic prostate cancer BALVERSA™ (erdafitinib) (US) Urothelial cancer	SPRAVATO™ (Esketamine) (EU) Treatment resistant depression	Niraparib Metastatic castration-resistant prostate cancer (mCRPC)	Ponesimod Monotherapy for multiple sclerosis
		BCMA CAR-T Multiple Myeloma	Seltorexant Adjunctive treatment for major depressive disorder
		BALVERSA™ (erdafitinib) (EU) Urothelial cancer	Infectious Diseases & Vaccines
Neuroscience		Lazertinib Non Small Cell Lung Cancer	Pimodivir Influenza A
SPRAVATO™ (Esketamine) (US) Treatment resistant depression		Cusatuzumab Acute myeloid leukemia	RSV Sr vaccine RSV vaccine
		JNJ-6372 (EGFR/cMET) Solid Tumor	Cardiovascular & Metabolism
		JNJ-7957 (BCMA/CD3), JNJ-7564 (GPRC5D/CD3) Multiple myeloma	CNGB3 and CNGA3 AAV Gene Therapy Achromatopsia
		Immunology	RPGR AAV Gene Therapy X-linked retinitis pigmentosa
		JNJ-4500 Anti-NKG2D Crohn's disease	Aprocitentan Difficult to treat hypertension

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; BCMA CAR-T licensed from Legend Biotech; Cusatuzumab licensed from Argenx; Lazertinib licensed from Yuhan Corporation; JNJ-4500 Anti-NKG2D licensed from Novo Nordisk; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; Seltorexant being developed in collaboration with Minerva Neurosciences; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (JNJ-6372, JNJ-7957, JNJ-7564)

